Disparity of physician specialties in the management of chronic heart failure: Trend analysis in Taiwan, 2000 - 2010

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 8, 2013, Pages 678-687

  Chou, Chia Yu ^a,c,d   Chen, Tzeng Ji ^a   Chiang, Shu Chiung ^a   Chen, Yu Chun ^a   Cheng, Ming Hui ^b   Yang, Yao Chia ^b   Wu, Cheng Hsueh ^a   Ho, Chin Chin ^b   Huang, Yu Ju ^b   Chou, Yueh Ching ^a,b,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Health insurance; Mortalityreducing drugs for heart failure; Pharmacotherapy for chronic heart failure; Physician specialties; Prescription patterns

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIHYDRALAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; NITRATE; PROPRANOLOL; SPIRONOLACTONE; VALSARTAN;

ADULT; AGED; ARTICLE; CARDIOLOGIST; FEMALE; GENERAL PRACTITIONER; HEART FAILURE; HUMAN; INTERNIST; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; POPULATION RESEARCH; PRESCRIPTION; TAIWAN; TREND STUDY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIGOXIN; FEMALE; HEART FAILURE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; SPECIALIZATION; TAIWAN; TIME FACTORS;

EID: 84883147267     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201762     Document Type: Article

References (36)

1. Konstam MA. Progress in heart failure Management? Lessons from the real world. Circulation. 2000; 102: 1076-1078. doi:10.1161/01.CIR.102.10.1076 PubMed
2. Konstam MA, Dracup K, Baker DW, Bottorff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF, Hadorn DC. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. J Card Fail. 1995; 1: 183-187. doi:10.1016/1071- 9164(95)90021-7 PubMed
3. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J. 1999; 20: 447-455. doi:10.1053/euhj.1998.1239 PubMed
4. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993; 22 (Suppl A): 6A-13A. doi:10.1016/0735-1097(93)90455-A PubMed
5. Eriksson H, Svärdsudd K, Larsson B, Ohlson LO, Tibblin G, Welin L, Wilhelmsen L. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J. 1989; 10: 647-656. PubMed
6. Landahl S, Svanborg A, Astrand K. Heart volume and the prevalence of certain common cardiovascular disorders at 70 and 75 years of age. Eur Heart J. 1984; 5: 326-331. PubMed
7. Huang CH, Chien KL, Chen WJ, Sung FC, Hsu HC, Su TC, Lee YT. Impact of heart failure and left ventricular function on long-term survival-report of a community-based cohort study in Taiwan. Eur J Heart Fail. 2007; 9: 587-593. doi:10.1016/j. ejheart.2007.02.008 PubMed
8. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Longterm trends in the incidence of and survival with heart failure. N Engl J Med. 2002; 347: 1397-1402. doi:10.1056/NEJMoa020265 PubMed
9. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21. doi:10.1056/NEJMoa1009492 PubMed
10. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004; 141: 693-704. PubMed
11. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E; ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACEinhibitor therapy in patients with heart failure or leftventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000; 355: 1575-1581. doi:10.1016/S0140-6736(00)02212-1 PubMed
12. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J et al; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14: 803-869. doi:10.1093/eurjhf/hfs105 PubMed
13. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119: 1977-2016. doi:10.1161/ CIRCULATIONAHA.109.192064 PubMed
14. Nair AP, Timoh T, Fuster V. Contemporary medical management of systolic heart failure. Circulation journal: official journal of the Japanese Circulation Society. 2012; 76: 268-277.
15. Cole RT, Kalogeropoulos AP, Georgiopoulou VV, Gheorghiade M, Quyyumi A, Yancy C, Butler J. Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation. 2011; 123: 2414-2422. doi:10.1161/CIRCULATIONAHA.110.012781 PubMed
16. Caccamo MA, Eckman PM. Pharmacologic therapy for New York Heart Association class IV heart failure. Congest Heart Fail. 2011; 17: 213-219. doi:10.1111/j.1751-7133.2011.00235.x PubMed
17. Arif SA, Mergenhagen KA, Del Carpio RO, Ho C. Treatment of systolic heart failure in the elderly: an evidence-based review. Ann Pharmacother. 2010; 44: 1604-1614. doi:10.1345/aph.1P128 PubMed
18. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008; 10: 933-989. doi:10.1016/j. ejheart.2008.08.005 PubMed
19. Wu TY, Majeed A, Kuo KN. An overview of healthcare system in Taiwan. London Journal of Primary Care. 2010; 3: 115-119.
20. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo, 2011.
21. de Freitas EV, Batlouni M, Gamarsky R. Heart failure in the elderly. J Geriatr Cardiol. 2012; 9: 101- 107. doi:10.3724/SP.J.1263.2011.12295 PubMed
22. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-1675. doi:10.1056/ NEJMoa010713 PubMed
23. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26: 215-225. doi:10.1093/eurheartj/ehi115 PubMed
24. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002; 106: 2194-2199. doi:10.1161/01. CIR.0000035653.72855.BF PubMed
25. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759-766. doi:10.1016/S0140-6736(03)14282-1 PubMed
26. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004; 351: 2049-2057. doi:10.1056/NEJMoa042934 PubMed
27. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: 1429- 1435. doi:10.1056/NEJM198706043162301 PubMed
28. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355: 1582- 1587. doi:10.1016/S0140-6736(00)02213-3 PubMed
29. Yao DK, Wang LX, Curran S, Ball P. Adherence to treatment guidelines in the pharmacological management of chronic heart failure in an Australian population. J Geriatr Cardiol. 2011; 8: 88-92. doi:10.3724/SP.J.1263.2011.00088 PubMed
30. Crawford T, Segars LW, Rasu RS. (In press). Prescribing trends for management of congestive heart failure from 2002 to 2004. Research in social & administrative pharmacy: RSAP. 2009. Retrieved from http://www.rsap.org/ article/S1551- 7411(09)00075-8/fulltext
31. Tseng DS, Kwong J, Rezvani F, Coates AO. Angiotensin-converting enzyme-related cough among Chinese-Americans. The American journal of medicine. 2010; 123: 183 e11-15.
32. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995; 40: 141-144. PubMed
33. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005; 112: 2426-2435. doi:10.1161/ CIRCULATIONAHA.105.582320 PubMed
34. Foody JM, Farrell MH, Krumholz HM. beta- Blocker therapy in heart failure: scientific review. JAMA. 2002; 287: 883-889. doi:10.1001/ jama.287.7.883 PubMed
35. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525-533. doi:10.1056/NEJM199702203360801 PubMed
36. Go AS, Rao RK, Dauterman KW, Massie BM. A systematic review of the effects of physician specialty on the treatment of coronary disease and heart failure in the United States. Am J Med. 2000; 108: 216-226. doi:10.1016/S0002- 9343(99)00430- 1 PubMed